| Home : ESMO 2022: Interim Results for Treatment of Platinum-Resistant Ovarian Cancer with p62 Plasmid DNA Show Statistically Significant Changes in Progression-Free Survival |
|
Sep 09
2022 |
ESMO 2022: Interim Results for Treatment of Platinum-Resistant Ovarian Cancer with p62 Plasmid DNA Show Statistically Significant Changes in Progression-Free Survival |
|
While the disease has progressed in all patients receiving standard of care, it did not progress in 40% of the patients receiving standard chemotherapy together with the experimental drug, Elenagen — and for half of the patients in the group, Elenagen has increased the time to disease... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/esmo-2022-interim-results-for-treatment-of-platinum-resistant-ovarian-cancer-with-p62-plasmid-dna-show-statistically-significant-changes-in-progression-free-survival-301620958.html |
| |
|
Related News
|
» CATL and BMW Group reach framework agreement on cylindrical battery supply
» Haivision Unveils New Branding to Reflect its Evolution and Strategic Direction
|
